Why Most Commercial Excellence Programmes in Medical Devices Fail to Change Rep Behaviour
In 2024, a top-five global medical device company completed a two-year commercial excellence transformation. They hired a boutique consultancy to redesign their selling methodology. They built a competency framework. They trained every rep across 14 markets. They launched a digital learning platform. The programme was internally celebrated. It won an industry training award.
Twelve months later, their win rates had not moved. Ramp time for new hires was unchanged. Procurement objection handling, the single competency they had identified as the biggest gap, showed no measurable improvement when assessed in field observations.
This is not unusual. It is the norm.
The pattern that repeats
Commercial excellence in medical devices has become an industry. Companies spend millions building sophisticated frameworks that describe what excellent selling looks like. They define competencies, map buyer journeys, align messaging to value propositions, and create visual models that explain the buying committee dynamics their reps face.
The frameworks are often excellent. The analysis is usually correct. The problem is not what they build. It is what happens after.
The typical deployment follows a predictable pattern. A workshop introduces the methodology. Reps attend, engage, and leave with positive feedback scores. An e-learning module reinforces the concepts. A certification test confirms knowledge retention. The programme is declared complete.
But knowledge is not capability. Understanding how to handle a procurement objection is fundamentally different from being able to do it fluently when a procurement director is staring at you across a table, pushing for a 15 percent price reduction and threatening to consolidate to your competitor.
The McKinsey Commercial Excellence practice has written extensively about this gap. Their research consistently shows that the difference between top-performing and average medical device sales organisations is not the quality of their frameworks. It is the consistency with which those frameworks are executed in live conversations.
Why knowledge does not transfer to behaviour
The cognitive science is clear. Knowledge and skill are processed differently in the brain. Knowledge is declarative: facts, frameworks, and models that can be recalled. Skill is procedural: the ability to execute under pressure without conscious deliberation.
The analogy is well-worn but apt. A surgeon who has read every textbook on knee replacement can describe the procedure in perfect detail. But they cannot perform surgery until they have practised. The hands need repetitions. The brain needs to build the neural pathways that enable fluid execution under time pressure and stress.
Selling is a performance skill. It plays out in real-time conversations where the rep must listen, process, formulate a response, and deliver it persuasively within seconds. No amount of e-learning changes the neural pathways that govern this real-time performance.
Research published in the Journal of Applied Psychology found that training interventions focused on knowledge produced effect sizes roughly half those of interventions that included behavioural rehearsal. The difference was not subtle. Practice-based approaches were approximately twice as effective at producing on-the-job behaviour change.
For commercial excellence teams in medical devices, this has a stark implication. Every framework you build, every competency you define, and every workshop you run will produce minimal behaviour change unless it is paired with sufficient deliberate practice.
What deliberate practice means in commercial context
Anders Ericsson's research on deliberate practice, spanning three decades and multiple performance domains, identifies four requirements for practice that actually builds skill.
First, the practice must be challenging enough to push beyond current capability. Easy repetitions do not create growth. A rep practising a conversation they can already handle fluently is not developing.
Second, there must be immediate, specific feedback. Without feedback, the rep does not know what to adjust. Generic encouragement is not feedback. Specific observations about what worked and what didn't allow targeted improvement.
Third, the practice must be repetitive enough to build automaticity. A single role play in a workshop is exposure, not practice. Building conversational fluency requires dozens of repetitions across varied situations.
Fourth, the practice must be focused on specific sub-skills. Practising an entire sales call is less effective than isolating procurement objection handling, or value articulation, or clinical evidence delivery as discrete skills to develop.
Most commercial excellence programmes in medical devices deliver none of these at scale. The workshop provides one or two role plays that are not sufficiently challenging because they use untrained peers as conversation partners. The feedback is delayed and generic. There is no mechanism for repetition. And the practice is not decomposed into sub-skills.
The scale problem
Even if a commercial excellence team recognises the need for practice, they face a structural problem: practice does not scale with traditional methods.
Manager-led coaching is the gold standard for development but is inherently limited. A regional sales manager responsible for 8-12 reps can observe perhaps one or two field visits per rep per month. That is not enough repetition to build skill. It is barely enough for assessment.
External trainers and coaches provide higher quality practice but at enormous cost. A three-day workshop with an external facilitator for 20 reps costs tens of thousands and provides perhaps 15-20 minutes of actual individual practice time per rep. The economics do not work for sustained skill development.
Peer practice groups offer better economics but suffer from the realism problem. Colleagues playing buyer roles do not behave like real procurement directors or surgeons. They lack the domain knowledge to challenge realistically and the acting skill to sustain pressure. Reps learn to handle easy objections from friendly colleagues, not difficult ones from sceptical buyers.
The result is that most medical device commercial excellence programmes default to knowledge transfer because it scales. Workshops, e-learning, and certifications can reach hundreds or thousands of reps efficiently. But efficient delivery of knowledge is not the same as effective development of skill.
What changes when practice becomes scalable
AI-powered conversation simulation solves the scale problem. Every rep in the organisation can access realistic practice with AI personas that behave like the buyers they actually face: surgeons who demand clinical evidence, procurement directors who push on price, hospital administrators who challenge ROI assumptions, and committee members who compare against competitors.
This is not role play with a chatbot. Modern AI simulation creates conversation partners that maintain persona consistency, adapt to rep responses in real time, and generate the kind of pressure and unpredictability that real buyer conversations produce.
For commercial excellence teams, this means several things.
The frameworks they build can now be practised, not just taught. A competency like "handles procurement pricing objections while maintaining value position" can be rehearsed dozens of times with an AI procurement director who challenges differently each time.
The gap between training events and field application closes. Instead of workshops followed by months of hoping reps apply what they learned, practice becomes continuous. Reps can rehearse specific conversations before they happen: a formulary review next Tuesday, a competitive displacement meeting on Thursday, a product launch presentation next month.
Assessment becomes possible at a granular level. Instead of measuring whether reps attended training, commercial excellence teams can measure whether reps can actually execute the behaviours the framework defines. The data shows who handles procurement objections fluently and who does not, regardless of what they scored on the certification test.
And the measurement creates a feedback loop that has never existed before. If the data shows that 70 percent of reps struggle with the same objection type, the commercial excellence team knows exactly where to focus their next intervention. They are no longer guessing about capability gaps. They can see them.
Building practice into the commercial excellence operating model
The most effective commercial excellence teams are beginning to treat practice as an operating capability, not an event. They are integrating it into the rhythm of their commercial organisation.
Before product launches, reps complete practice scenarios that confirm they can articulate the new value proposition and handle likely competitive objections. Launch readiness is measured by conversational capability, not quiz scores.
Before formulary reviews, reps assigned to key accounts practise their committee presentation with AI personas playing the committee members they will face. They rehearse health economic arguments, anticipate challenges, and refine their approach before the stakes are real.
During onboarding, new reps start practising from week one. They do not wait months for enough field experience to accumulate. They build conversational fluency with AI surgeon and procurement personas in parallel with their product training.
As ongoing development, reps have access to practice scenarios relevant to their current challenges. A rep struggling with a particular competitive situation can practise it repeatedly until they find an approach that works.
The commercial excellence team's role shifts from designing and delivering training events to managing a capability-building system. They monitor skill data, identify gaps, deploy targeted practice interventions, and measure the impact on commercial outcomes.
The commercial case for practice
For Commercial Directors and Heads of Commercial Excellence, the business case is straightforward. If the only variable that reliably changes selling behaviour is deliberate practice, and your current programmes do not include it, then you are investing heavily in an approach that the evidence says will not work.
The alternative is not to abandon your frameworks. They provide the architecture. The competencies are correct. The buyer journey mapping is valuable. The messaging frameworks are sound.
The addition is practice at scale. Give every rep in your organisation the ability to rehearse the conversations your framework defines as excellent, get immediate feedback against your specific standards, and repeat until those behaviours become automatic.
Platforms like TrainBox make this operationally possible for the first time. A global medical device organisation can deploy practice scenarios to hundreds of reps across dozens of markets, measure capability development against their specific competency model, and connect practice data to business outcomes.
The question for commercial excellence leaders is no longer whether practice works. The evidence is unambiguous. The question is whether you will continue investing in programmes that build knowledge without building skill, or whether you will add the practice layer that actually changes behaviour.
TrainBox helps medical device teams practise real conversations so they're ready when it matters.